Dr. David Hong, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Albert Einstein College Of Medicine

  Medical School, 1999

• Use of expansion cohorts in phase 1 trials and probability of success in phase 2 for 381 anticancer drugs, 2017-04-04

• Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses, 2019-10-28

• Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study, 2021-03-19

• Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial, 2019-02-07

• Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors, 2014-11-04

• A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours, 2014-10-23

• Prognostic implications ofRASalterations in diverse malignancies and impact of targeted therapies, 2020-01-29

• METnucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors, 2013-12-11

• Inhibition of the CD47-SIRPa axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data, 2022-11-11

• Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors, 2017-11-21

• The isolation and characterization of CTC subsets related to breast cancer dormancy, 2015-12-03

• Factors Affecting Symptom Presentation in an Early-Phase Clinical Trials Clinic Patient Population, 2019-11-25

• TargetingERBB2(HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications, 2019-10-21

• Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients, 2015-07-08

• Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma Larotrectinib for TRK fusion thyroid carcinoma, 2022-03-25

• Strategies for combining immunotherapy with radiation for anticancer therapy, 2015-08-27

• Erratum: Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions, 2019-01-29

• Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies, 2015-02-25

• PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes, 2012-11-30

• Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma, 2019-09-18

• METaberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit, 2014-03-16

• TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma, 2019-11-26

• Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis, 2020-11-04

• Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma, 2018-04-11

• Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine, 2019-12-30

• Mechanisms of resistance to KRASG12C-targeted therapy, 2021-04-05

• Clinical Characteristics and Outcomes of Pediatric Oncology Patients with Aggressive Biology Enrolled in Phase I Clinical Trials Designed for Adults: The University of Texas MD Anderson Cancer Center Experience, 2014-07-27

• Clinical next generation sequencing to identify actionable aberrations in a phase I program, 2015-05-08

• STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial., 2018-11-16

• Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas, 2017-04-05

• A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors, 2022-04-14

• Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma, 2015-07-13

• Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies, 2022-02-25

• Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, 2020-02-24

• Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study, 2021-11-03

• Autologous T cell therapy for MAGE-A4+solid cancers in HLA-A*02+patients: a phase 1 trial, 2023-01-09

• Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis, 2022-04-07

• Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study, 2021-09-25

• Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials, 2020-09-01

• Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer withBRAFV600Emutation, 2016-10-11

• Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies, 2016-10-17

• Phase I trials as valid therapeutic options for patients with cancer, 2019-09-02

• Post-discharge survival outcomes of patients with advanced cancer from UT MD Anderson Cancer Center Investigational Cancer Therapeutics (phase I trials) Inpatient unit, 2016-11-02

• Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers, 2017-10-19

• Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway, 2014-03-14

• First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors, 2020-09-28

• Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors, 2018-06-22

• Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial, 2020-04-20

• A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Patients with Solid Tumors, 2018-04-03

• Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience, 2017-11-21

• Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma, 2015-10-15

• A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer, 2014-10-18

• Bevacizumab-Based Treatment in Colorectal Cancer with aNRASQ61K Mutation, 2013-02-12

• BRAFmutation testing with a rapid, fully integrated molecular diagnostics system, 2015-07-27

• Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-TypeEGFRor Resistant Mutations, 2013-08-20

• A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors, 2021-08-05

• Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer andPIK3CAmutations, 2013-10-03

• Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours, 2020-04-02

• Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape, 2017-06-23

• Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology, 2022-10-27

• PIK3CAMutations Frequently Coexist withRASandBRAFMutations in Patients with Advanced Cancers, 2011-07-29

• Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer, 2018-01-31

• Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors, 2021-12-29

• Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases, 2011-04-18

• A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies, 2021-11-16

• Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers, 2017-12-13

• Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver, 2015-05-21

• Analysis ofMETGenetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit, 2014-06-23

• Activity of Brigatinib in Crizotinib and Ceritinib-ResistantROS1-Rearranged Non-Small-Cell Lung Cancer, 2019-02-15

• BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study, 2023-02-18

• Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells, 2017-06-07

• Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials, 2016-07-28

• Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer, 2022-08-02

• Predicting Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Enrolled in Early Phase Immunotherapy Trials, 2018-04-11

• PIK3CA, and PTEN Aberrations in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors: Experience with 1,656 Patients at MD Anderson Cancer Center, 2014-01-16

• Clinical trial characteristics and barriers to participant accrual: The MD Anderson Cancer Center experience over 30 years, a historical foundation for trial improvement, 2017-03-08

• Identification ofKRASG12CMutations in Circulating Tumor DNA in Patients With Cancer, 2022-07-21

• Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors, 2022-03-18

• A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden, 2021-01-04

• KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors, 2012-05-31

• Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials, 2017-12-19

• An appraisal of drug development timelines in the Era of precision oncology, 2016-07-13

• Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions, 2017-05-05

• Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies, 2023-04-18

• Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies, 2013-08-02

• Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study, 2017-09-08

• Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers, 2018-04-13

• Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer, 2017-05-23

• P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy, 2013-05-01

• Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers, 2018-07-17

• METabnormalities in patients with genitourinary malignancies and outcomes withc-METinhibitors, 2014-07-03

• The next generation of KRAS targeting: reasons for excitement and concern, 2022-11-03

• Radiomics to predict immunotherapy-induced pneumonitis: Proof of concept, 2017-10-27

• Body Composition, Symptoms, and Survival in Advanced Cancer Patients Referred to a Phase I Service, 2012-01-03

• Characteristics and survival of patients with advanced cancer and p53 mutations, 2014-05-25

• Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer, 2017-10-19

• PIK3CAmutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials, 2012-10-12

• FBXW7Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors, 2014-02-19

• Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy, 2016-08-31

• Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial, 2022-08-23

• Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies, 2017-04-18

• Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials, 2015-06-23

• Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors, 2018-11-13

• Molecular characterization of breast cancer CTCs associated with brain metastasis, 2017-08-04

• Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy, 2019-09-04

• Phase I Study of Anti-VEGF Monoclonal Antibody Bevacizumab and Histone Deacetylase Inhibitor Valproic Acid in Patients with Advanced Cancers, 2014-01-17

• A Phase I Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies, 2021-03-26

• Prognostic Impact of Radiation Therapy to the Primary Tumor in Patients With Non-small Cell Lung Cancer and Oligometastasis at Diagnosis, 2012-04-13

• TargetingBRAFMutant Colorectal Cancer: Progress in Combination Strategies, 2017-02-07

• Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma, 2017-09-06

• Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype, 2020-09-11

• Outcomes of patients with advanced cancer andKRASmutations in phase I clinical trials, 2014-08-10

• Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors, 2020-10-28

• Phase I Clinical Trial of Lenalidomide in Combination with Sorafenib in Patients with Advanced Cancer, 2013-06-12

• Associations between the gut microbiome and fatigue in cancer patients, 2021-03-12

• Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27 dependent pathway, 2018-01-04

• Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses, 2014-07-01

• Genomics, morphoproteomics, and treatment patterns of alveolar soft part sarcoma patients and response to multiple experimental therapies, 2020-03-03

• Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus, 2014-03-20

• Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors, 2012-03-31

• Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic, 2018-09-04